Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation
Objectives In resectable pancreatic ductal adenocarcinoma (PDAC), few pre-operative prognostic biomarkers are available. Radiomics has demonstrated potential but lacks external validation. We aimed to develop and externally validate a pre-operative clinical-radiomic prognostic model. Methods Retrospective international, multi-center study in resectable PDAC. The training cohort included 352 patients (pre-operative CTs from five Canadian hospitals). Cox models incorporated (a) pre-operative clinical variables (clinical), (b) clinical plus CT-radiomics, and (c) post-operative TNM model, which served as the reference. Outcomes were overall (OS)/disease-free survival (DFS). Models were assessed in the validation cohort from Ireland (n = 215, CTs from 34 hospitals), using C-statistic, calibration, and decision curve analyses. Results The radiomic signature was predictive of OS/DFS in the validation cohort, with adjusted hazard ratios (HR) 2.87 (95% CI: 1.40–5.87, p < 0.001)/5.28 (95% CI 2.35–11.86, p < 0.001), respectively, along with age 1.02 (1.01–1.04, p = 0.01)/1.02 (1.00–1.04, p = 0.03). In the validation cohort, median OS was 22.9/37 months (p = 0.0092) and DFS 14.2/29.8 (p = 0.0023) for high-/low-risk groups and calibration was moderate (mean absolute errors 7%/13% for OS at 3/5 years). The clinical-radiomic model discrimination (C = 0.545, 95%: 0.543–0.546) was higher than the clinical model alone (C = 0.497, 95% CI 0.496–0.499, p < 0.001) or TNM (C = 0.525, 95% CI: 0.524–0.526, p < 0.001). Despite superior net benefit compared to the clinical model, the clinical-radiomic model was not clinically useful for most threshold probabilities. Conclusion A multi-institutional pre-operative clinical-radiomic model for resectable PDAC prognostication demonstrated superior net benefit compared to a clinical model but limited clinical utility at external validation. This reflects inherent limitations of radiomics for PDAC prognostication, when deployed in real-world settings. Key Points • At external validation, a pre-operative clinical-radiomics prognostic model for pancreatic ductal adenocarcinoma (PDAC) outperformed pre-operative clinical variables alone or pathological TNM staging. • Discrimination and clinical utility of the clinical-radiomic model for treatment decisions remained low, likely due to heterogeneity of CT acquisition parameters. • Despite small improvements, prognosis in PDAC using state-of-the-art radiomics methodology remains challenging, mostly owing to its low discriminative ability. Future research should focus on standardization of CT protocols and acquisition parameters..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
---|---|
Enthalten in: |
European radiology - 32(2021), 4 vom: 10. Nov., Seite 2492-2505 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Healy, Gerard M. [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
External validation |
---|
Anmerkungen: |
© European Society of Radiology 2021 |
---|
doi: |
10.1007/s00330-021-08314-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR04645926X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR04645926X | ||
003 | DE-627 | ||
005 | 20230519143814.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220315s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00330-021-08314-w |2 doi | |
035 | |a (DE-627)SPR04645926X | ||
035 | |a (SPR)s00330-021-08314-w-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Healy, Gerard M. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © European Society of Radiology 2021 | ||
520 | |a Objectives In resectable pancreatic ductal adenocarcinoma (PDAC), few pre-operative prognostic biomarkers are available. Radiomics has demonstrated potential but lacks external validation. We aimed to develop and externally validate a pre-operative clinical-radiomic prognostic model. Methods Retrospective international, multi-center study in resectable PDAC. The training cohort included 352 patients (pre-operative CTs from five Canadian hospitals). Cox models incorporated (a) pre-operative clinical variables (clinical), (b) clinical plus CT-radiomics, and (c) post-operative TNM model, which served as the reference. Outcomes were overall (OS)/disease-free survival (DFS). Models were assessed in the validation cohort from Ireland (n = 215, CTs from 34 hospitals), using C-statistic, calibration, and decision curve analyses. Results The radiomic signature was predictive of OS/DFS in the validation cohort, with adjusted hazard ratios (HR) 2.87 (95% CI: 1.40–5.87, p < 0.001)/5.28 (95% CI 2.35–11.86, p < 0.001), respectively, along with age 1.02 (1.01–1.04, p = 0.01)/1.02 (1.00–1.04, p = 0.03). In the validation cohort, median OS was 22.9/37 months (p = 0.0092) and DFS 14.2/29.8 (p = 0.0023) for high-/low-risk groups and calibration was moderate (mean absolute errors 7%/13% for OS at 3/5 years). The clinical-radiomic model discrimination (C = 0.545, 95%: 0.543–0.546) was higher than the clinical model alone (C = 0.497, 95% CI 0.496–0.499, p < 0.001) or TNM (C = 0.525, 95% CI: 0.524–0.526, p < 0.001). Despite superior net benefit compared to the clinical model, the clinical-radiomic model was not clinically useful for most threshold probabilities. Conclusion A multi-institutional pre-operative clinical-radiomic model for resectable PDAC prognostication demonstrated superior net benefit compared to a clinical model but limited clinical utility at external validation. This reflects inherent limitations of radiomics for PDAC prognostication, when deployed in real-world settings. Key Points • At external validation, a pre-operative clinical-radiomics prognostic model for pancreatic ductal adenocarcinoma (PDAC) outperformed pre-operative clinical variables alone or pathological TNM staging. • Discrimination and clinical utility of the clinical-radiomic model for treatment decisions remained low, likely due to heterogeneity of CT acquisition parameters. • Despite small improvements, prognosis in PDAC using state-of-the-art radiomics methodology remains challenging, mostly owing to its low discriminative ability. Future research should focus on standardization of CT protocols and acquisition parameters. | ||
650 | 4 | |a Radiomics |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pancreatic adenocarcinoma |7 (dpeaa)DE-He213 | |
650 | 4 | |a Survival |7 (dpeaa)DE-He213 | |
650 | 4 | |a External validation |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pre-operative |7 (dpeaa)DE-He213 | |
700 | 1 | |a Salinas-Miranda, Emmanuel |4 aut | |
700 | 1 | |a Jain, Rahi |4 aut | |
700 | 1 | |a Dong, Xin |4 aut | |
700 | 1 | |a Deniffel, Dominik |4 aut | |
700 | 1 | |a Borgida, Ayelet |4 aut | |
700 | 1 | |a Hosni, Ali |4 aut | |
700 | 1 | |a Ryan, David T. |4 aut | |
700 | 1 | |a Njeze, Nwabundo |4 aut | |
700 | 1 | |a McGuire, Anne |4 aut | |
700 | 1 | |a Conlon, Kevin C. |4 aut | |
700 | 1 | |a Dodd, Jonathan D. |4 aut | |
700 | 1 | |a Ryan, Edmund Ronan |4 aut | |
700 | 1 | |a Grant, Robert C. |4 aut | |
700 | 1 | |a Gallinger, Steven |4 aut | |
700 | 1 | |a Haider, Masoom A. |0 (orcid)0000-0002-7165-8315 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European radiology |d Berlin : Springer, 1991 |g 32(2021), 4 vom: 10. Nov., Seite 2492-2505 |w (DE-627)SPR00395112X |w (DE-600)1472718-3 |x 1432-1084 |7 nnns |
773 | 1 | 8 | |g volume:32 |g year:2021 |g number:4 |g day:10 |g month:11 |g pages:2492-2505 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00330-021-08314-w |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 32 |j 2021 |e 4 |b 10 |c 11 |h 2492-2505 |